Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)

被引：3
|
作者：
Sauter, Craig S. [1 ]
Riviere, Isabelle [1 ]
Bernal, Yvette J. [1 ]
Wang, Xiuyan [1 ]
Purdon, Terence J. [1 ]
Yoo, Sarah [1 ]
Moskowitz, Craig H. [1 ]
Giralt, Sergio [1 ]
Matasar, Matthew J. [1 ]
Curran, Kevin J. [1 ]
Park, Jae H. [1 ]
Sadelain, Michel [1 ]
Brentjens, Renier J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Chimeric Antigen Receptor (CAR) T Cell Therapy Followed by Hematopoietic Stem Cell Transplantation May Improve Progression free Survival in Patients with Relapse/Refractory B-cell Non-hodgkin Lymphoma
    Huang, Haiwen
    Liu, Shuo
    Zhu, Qian
    Duan, Yishan
    Wu, Depei
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 241 - 242
  • [32] CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas
    Onea, Alexandra S.
    Jazirehi, Ali R.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (02): : 403 - 424
  • [33] Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma
    Kim, Ki Hyun
    Yoon, Dok Hyun
    Jo, Jae-Cheol
    Jeong, Seong Hyun
    Oh, Sung Yong
    Cho, Hyungwoo
    Choi, Yoon Seok
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Cui, LeiGuang
    Lee, Tae-Bum
    Hwang, In-Sik
    Lee, Young-Ha
    Lee, Yong-Jun
    Lee, Yoon
    Kim, Jong-Hoon
    Lee, Jong-Seo
    Chung, Junho
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma
    Yang, Fan
    Shi, Hui
    Lei, Yang
    Li, Ruiting
    Xu, Teng
    Deng, Biping
    Wu, Tong
    Ke, Xiaoyan
    Hu, Kai
    BLOOD, 2021, 138
  • [35] DIRECT COMPARISON OF IN VIVO FATE OF SECOND AND THIRD-GENERATION CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS IN PATIENTS WITH B CELL NON-HODGKIN LYMPHOMA (B-NHL): REVERSAL OF TOXICITY FROM TONIC SIGNALING
    da Silva, D. Gomes
    Mukherjee, M.
    Madhuwanti, S.
    Dakhova, O.
    Liu, H.
    Grilley, B.
    Gee, A.
    Neelapu, S. S.
    Rooney, C.
    Heslop, H.
    Savoldo, B.
    Dotti, G.
    Brenner, M.
    Mamonkin, M.
    Ramos, C. A.
    CYTOTHERAPY, 2017, 19 (05) : S9 - S9
  • [36] Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma
    Xu, Hao
    Lv, Qiuxia
    Huang, Liang
    Cao, Wenyue
    Wang, Jue
    Meng, Fankai
    Li, Chunrui
    Zheng, Miao
    Chen, Liting
    Mu, Ketao
    Cheng, Jiali
    Zhu, Li
    Zhou, Jianfeng
    Zhang, Yicheng
    Wang, Na
    Cao, Yang
    CYTOTHERAPY, 2023, 25 (02) : 185 - 191
  • [37] Comprehensive Salvage Radiotherapy for Limited Relapsed B-Cell Non-Hodgkin Lymphoma Following CD19 Chimeric Antigen Receptor T-Cell Therapy
    Saifi, O.
    Breen, W.
    Lester, S. C.
    Rule, W. G.
    Stish, B. J.
    Rosenthal, A.
    Munoz, J.
    Lin, Y.
    Bennani, N.
    Paludo, J.
    Khurana, A.
    Bisneto, J. Villasboas
    Johnston, P.
    Ansell, S. M.
    Iqbal, M.
    Moustafa, M. Alhaj
    Murthy, H. S.
    Kharfan-Dabaja, M.
    Hoppe, B. S.
    Peterson, J. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S56 - S56
  • [38] How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells
    Nagler, Arnon
    Perriello, Vincenzo Maria
    Falini, Lorenza
    Falini, Brunangelo
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) : 396 - 410
  • [39] In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).
    Saifi, Omran
    Breen, William
    Lester, Scott
    Rule, William G.
    Stish, Brad J.
    Rosenthal, Allison Claire
    Munoz, Javier
    Lin, Yi
    Bennani, Nabila Nora
    Paludo, Jonas
    Khurana, Arushi
    Villasboas, Jose Caetano
    Johnston, Patrick B.
    Ansell, Stephen M.
    Iqbal, Madiha
    Moustafa, Muhamad Alhaj
    Murthy, Hemant S.
    Kharfan-Dabaja, Mohamed
    Hoppe, Bradford
    Peterson, Jennifer
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Survival Outcomes for Patients with Relapsed/Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells
    Landsburg, Daniel J.
    Nasta, Sunita D.
    Svoboda, Jakub
    Gerson, James N.
    Schuster, Stephen J.
    Barta, Stefan K.
    Chong, Elise A.
    Lippo, Heather Di fi
    Weber, Elizabeth
    Cunningham, Kathleen
    Catania, Christopher
    Garfall, Alfred L.
    Stadtmauer, Edward A.
    V. Frey, Noelle
    Porter, David L.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (08): : 495 - 503
12345